---
id: "claim-chinese-trials-efficiency"
type: "claim"
source_timestamps: ["§ The Rise of Chinese Competition", "¶5"]
tags: ["metrics", "clinical-trials", "cost-efficiency"]
related: ["concept-china-pharma-ascendance", "quote-beijing-boston"]
confidence: "high"
testable: true
enrichment_status: "not fully validated — the specific 40%/50% figures are not corroborated by enrichment sources; the broader faster-execution + strong-enrollment direction is consistent"
speakers: ["Anaeze C. Offodile II", "Kushal T. Kadakia", "Yashodhara Dash", "Whitney Snider", "Joseph C. Wu", "Selwyn M. Vickers"]
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# Chinese clinical trials are significantly faster and cheaper than alternatives

Drugmakers are partnering with Chinese hospitals because their clinical trials are approximately **40% less expensive** and **50% faster** to conduct, while simultaneously offering **greater patient enrollment** than traditional Western trial sites. This is the operational engine behind [[concept-china-pharma-ascendance]] and the imagery in [[quote-beijing-boston]].

**Confidence (as stated in source):** high · **Testable:** yes.

**Enrichment verdict — not fully validated:** the exact **40% cheaper / 50% faster** figures are **not corroborated** by the provided enrichment sources and need independent verification. The broader idea — that China offers faster operational execution and strong enrollment capacity — is consistent with the article's argument. A counter-perspective ([[contrarian-institutional-model-flaw]] discussion) notes one study found academic R&D efficiency broadly consistent with industry, differing mainly in **slower trial duration**, and that out-of-pocket clinical-trial costs are only a small part of total drug cost.


## Related across articles
- [[claim-cost-efficiency-advantage]]